insulin detemir + liraglutide + metformin

This is a **combination therapy** of three medications—**insulin detemir**, **liraglutide**, and **metformin**—used in the management of type 2 diabetes mellitus. - **Insulin detemir** is a long-acting recombinant human insulin analog that regulates blood glucose by facilitating uptake of glucose into tissues and inhibiting hepatic glucose production. - **Liraglutide** is a glucagon-like peptide 1 receptor agonist (GLP-1 RA), enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and reducing gastric emptying. - **Metformin** is a biguanide antidiabetic agent; it reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity. No fixed-dose combination of all three exists as a single product, but the regimen has been studied in clinical trials as a multi-drug approach for patients with type 2 diabetes inadequately controlled on metformin and liraglutide alone. In such cases, **insulin detemir is added to the pre-existing combination of liraglutide and metformin** to improve glycemic control[1][2][3].